We focus on bringing cleverly-designed medicines to patients with the most difficult-to-treat cancers.
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers, including refractory renal cell carcinoma and non-small cell lung cancer.
Our seasoned team of biopharma industry leaders are dedicated to developing new oncology medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases includes inventors and scientists who developed the anti-cancer medicines, Rituxan (rituximab), Imbruvica (ibrutinib) and Zelboraf (vemurafenib).
Founded in 2014, Corvus has rapidly developed a deep pipeline of potentially breakthrough investigational medicines designed to be potent, selective and convenient to administer. We have efficiently moved our investigational medicines into the clinic and are conducting intelligently-designed, rigorously-conducted clinical trials at leading institutions.
Our approach to developing cancer medicines includes combining rigorous science and clinical research with development of biomarkers that potentially allow us to better select the optimum dose, best schedule and most appropriate patients. Our approach includes:
- Evaluating our investigational therapeutics in rigorously-conducted, hypothesis-driven clinical trials both as monotherapy and combination therapy
- Assessing the safety and efficacy of our medicines in some of the sickest cancer patients first and then advancing to earlier lines of treatment
- Designing efficient studies based on the identification of biomarkers that can be used to optimize dose, schedule and patient selection
- Continuing to grow our pipeline not only through internal discovery but also by seeking new opportunities through in-licensing